Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2003 | 1 |
2014 | 2 |
2015 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study.
Cancer. 2014 Aug 15;120(16):2448-56. doi: 10.1002/cncr.28728. Epub 2014 May 2.
Cancer. 2014.
PMID: 24797726
Free PMC article.
Clinical Trial.
The overall objective response rate was 2.5% (95% confidence interval, 0.7%-6.2%). Partial responses were observed in 4 patients, including 2 patients with OS, 1 patient with RMS, and 1 patient with alveolar soft part sarcoma. ...CONCLUSIONS: R1507 is safe and well tolerat …
The overall objective response rate was 2.5% (95% confidence interval, 0.7%-6.2%). Partial responses were observed in 4 patients, inc …
Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
Kim A, Widemann BC, Krailo M, Jayaprakash N, Fox E, Weigel B, Blaney SM.
Kim A, et al.
Pediatr Blood Cancer. 2015 Sep;62(9):1562-6. doi: 10.1002/pbc.25548. Epub 2015 Apr 27.
Pediatr Blood Cancer. 2015.
PMID: 26207356
Free PMC article.
Clinical Trial.
RESULTS: Twenty patients (median age of 11 years; range, 5-21) enrolled. No objective responses (RECIST) were observed in the 10 evaluable patients enrolled in each of the two primary disease strata of rhabdomyosarcoma and Wilms tumor. ...Single agent sorafenib was inactiv …
RESULTS: Twenty patients (median age of 11 years; range, 5-21) enrolled. No objective responses (RECIST) were observed in the 10 eval …
Item in Clipboard
Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profiling.
Park S, Lee J, Do IG, Jang J, Rho K, Ahn S, Maruja L, Kim SJ, Kim KM, Mao M, Oh E, Kim YJ, Kim J, Choi YL.
Park S, et al.
Sci Rep. 2014 Jan 10;4:3623. doi: 10.1038/srep03623.
Sci Rep. 2014.
PMID: 24406431
Free PMC article.
Comparative genomic hybridization array analysis revealed prominent amplification in the 12q13-14 region, and more specifically, the CDK4 proto-oncogene was highly amplified. ALK overexpression was observed at both protein and RNA levels. However, an ALK fusion assay using …
Comparative genomic hybridization array analysis revealed prominent amplification in the 12q13-14 region, and more specifically, the CDK4 pr …
Item in Clipboard
Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation.
Misawa A, Hosoi H, Tsuchiya K, Iehara T, Sawada T, Sugimoto T.
Misawa A, et al.
Pediatr Hematol Oncol. 2003 Mar;20(2):151-5. doi: 10.1080/0880010390158658.
Pediatr Hematol Oncol. 2003.
PMID: 12554526
A 17-year-old girl developed refractory rhabdomyosarcoma. An allogeneic peripheral-blood stem-cell transplant was performed after a myeloablative regimen. ...Although further investigation is required, allogeneic stem-cell transplantation could provide a new therape …
A 17-year-old girl developed refractory rhabdomyosarcoma. An allogeneic peripheral-blood stem-cell transplant was performed af …
Item in Clipboard
Cite
Cite